EAU 2018

EAU 2018: Quality of Life of Spouses Living with Men Undergoing Androgen Deprivation Therapy for Prostate Cancer

Introduction and Objectives: Men with prostate cancer undergoing androgen deprivation therapy (ADT) offered a supervised group-based exercise program as standard of care at our department. A previous questionnaire survey by the spouses to these men, show that the quality of life (Qol) of > 40% of the spouses are reduced. Therefore, the objective of this study was to investigate what factors that affect the experienced Qol by the spouses of men with prostate cancer undergoing ADT and attending a supervised group-based exercise program. And in which way we as Health professionals can help reduce the factors that affect quality of life in a negative way.

EAU 2018: Prostate Specific Membrane Antigen (PSMA) Expression in Transitional Cell Carcinoma (TCC) – Who Puts The S in PSMA?

Copenhagen, Denmark (UroToday.com) PSMA (prostate-specific membrane antigen) is a unique molecular specific to prostate tissue that has enabled novel imaging for prostate cancer, specifically in the setting of biochemical recurrence. PSMA-targeted PET scans, used for both diagnosis and potentially treatment, have been increasingly utilized in the setting of early biochemical recurrence, and in some cases, for staging purposes. As such, it has revolutionized prostate cancer management.

EAU 2018: Is There Finally an Increasing Survival of Patients With Urinary Bladder Cancer? A Nationwide Study in Sweden 1997–2016

Copenhagen, Denmark (UroToday.com) Bladder cancer has been one malignancy that has not seen significant improvement in outcomes over the past few decades. Despite the introduction of neoadjuvant chemotherapy and its slight benefit in appropriate patients, bladder cancer as a whole has remained relatively unchanged.

EAU 2018: Utilization and Outcomes of Chemoprophylaxis for the Prevention of Venous Thromboembolism Following Radical Cystectomy: A Population-Based Study

Copenhagen, Denmark (UroToday.com) Venous thromboembolic events (VTE) following radical cystectomy (RC) can be disastrous. A large body of evidence points to the increased risk that these patients have after extensive pelvic surgery, and prospective evidence has recently shown that immediate post-operative chemical VTE prophylaxis followed by 4 weeks of postoperative prophylaxis significantly decreases VTE rates with minimal increases in bleeding risks. 

EAU 2018: Disease and Patient’s Characteristics In Elderly (≥75 Years) Treated with Radical Cystectomy: Results of a Large Multicentre Retrospective Series

Copenhagen, Denmark (UroToday.com) The median age at diagnosis of bladder cancer is 70 years, and this age is shifting upward in many parts of the world with ageing populations. Hence, radical cystectomy (RC), which is the gold standard for muscle-invasive bladder cancer (MIBC), needs to be carefully monitored for safety in the elderly. That said, a large body of observational evidence does seem to show that RC is safe in the elderly, and should not be denied to a patient solely based on age.

EAU 2018: Prognostic Value of Concomitant Carcinoma in Situ in Radical Cystectomy Specimens on Patients with Bladder Cancer: A Meta-Analysis Of 24,136 Patients

Copenhagen, Denmark (UroToday.com) Carcinoma in situ (CIS) is a well-known risk factor for progression in patients with non-muscle invasive bladder cancer (NMIBC). The presence of CIS has also been identified as a poor prognostic factor for patients with invasive disease undergoing bladder-sparing therapy (TURBT+Chemo+XRT). The role of concomitant CIS in patients with invasive disease undergoing cystectomy remains largely unknown. In this poster presentation, the authors present a meta-analysis of assessing the association of   concomitant CIS in the radical cystectomy with overall survival (OS), recurrence free survival (RFS), cancer specific survival (CSS) and ureter involvement.

EAU 2018: Complete Transurethral Resection of the Bladder Before Radical Cystectomy Improves Oncological Outcomes

Copenhagen, Denmark (UroToday.com) Pathological downstaging has been associated with improved recurrence-free and cancer-specific survival in patients with invasive bladder cancer. It has been reported that approximately 15-20% of patients can be downstaged to pT0 following a complete transurethral resection of bladder tumor (TURBT). Moreover, a complete resection prior to cystectomy may also decrease the risk of local recurrences as it would prevent tumor potential tumor seeding at the time of cystectomy. The author's abstract aims to assess the oncological outcomes of patients who underwent a complete TURBT prior to radical cystectomy.